



Market Announcement

2 August 2023

Mesoblast Limited (ASX: MSB) – Trading Halt

Description

The securities of Mesoblast Limited ('MSB') will be placed in trading halt at the request of MSB, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 4 August 2023 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Adviser, Listings Compliance

2 August 2023

Ms Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4 Rialto North Tower
525 Collins Street
Melbourne VIC 3000

Copy: tradinghaltsmelbourne@asx.com.au

Dear Melissa,

Request for trading halt for Mesoblast Limited (ASX: MSB)

Pursuant to ASX Listing Rule 17.1, Mesoblast Limited ACN 109 431 870 (ASX: MSB; NASDAQ: MESO) (the **Company**) requests a trading halt in its securities effective immediately pending an announcement by the Company in relation to the U.S. Food and Drug Administration's review of its Biologics License Application resubmission for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease.

For the purposes of Listing Rule 17.1, the Company provides the following information:

- (a) the trading halt is requested pending an announcement in relation to the matters above;
- (b) the Company requests that the trading halt continues until the earlier of it making an announcement regarding the matters above and the commencement of trading on Friday, 4 August 2023; and
- (c) the Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely

A handwritten signature in black ink, appearing to read "Niva Sivakumar", written over a light blue circular stamp.

Niva Sivakumar
Company Secretary
Mesoblast Limited